As of 2025-06-21, the EV/EBITDA ratio of Ultragenyx Pharmaceutical Inc (RARE) is -6.26. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RARE's latest enterprise value is 3,384.16 mil USD. RARE's TTM EBITDA according to its financial statements is -540.93 mil USD. Dividing these 2 quantities gives us the above RARE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.9x - 12.4x | 12.2x |
| Forward P/E multiples | 20.2x - 43.4x | 31.8x |
| Fair Price | (114.24) - (69.61) | (124.39) |
| Upside | -407.6% - -287.4% | -434.9% |
| Date | EV/EBITDA |
| 2025-06-06 | -6.26 |
| 2025-06-05 | -6.22 |
| 2025-06-04 | -6.16 |
| 2025-06-03 | -6.13 |
| 2025-06-02 | -6.08 |
| 2025-05-30 | -5.71 |
| 2025-05-29 | -5.89 |
| 2025-05-28 | -5.77 |
| 2025-05-27 | -5.90 |
| 2025-05-23 | -6.00 |
| 2025-05-22 | -5.97 |
| 2025-05-21 | -5.95 |
| 2025-05-20 | -6.29 |
| 2025-05-19 | -6.09 |
| 2025-05-16 | -5.99 |
| 2025-05-15 | -5.85 |
| 2025-05-14 | -5.83 |
| 2025-05-13 | -5.95 |
| 2025-05-12 | -6.07 |
| 2025-05-09 | -5.90 |
| 2025-05-08 | -6.05 |
| 2025-05-07 | -5.61 |
| 2025-05-06 | -5.89 |
| 2025-05-05 | -6.56 |
| 2025-05-02 | -6.63 |
| 2025-05-01 | -6.58 |
| 2025-04-30 | -6.58 |
| 2025-04-29 | -6.42 |
| 2025-04-28 | -6.40 |
| 2025-04-25 | -6.42 |
| 2025-04-24 | -6.34 |
| 2025-04-23 | -6.29 |
| 2025-04-22 | -6.04 |
| 2025-04-21 | -5.95 |
| 2025-04-17 | -6.00 |
| 2025-04-16 | -5.88 |
| 2025-04-15 | -5.94 |
| 2025-04-14 | -5.87 |
| 2025-04-11 | -5.73 |
| 2025-04-10 | -5.56 |
| 2025-04-09 | -5.69 |
| 2025-04-08 | -5.19 |
| 2025-04-07 | -5.38 |
| 2025-04-04 | -5.43 |
| 2025-04-03 | -5.90 |
| 2025-04-02 | -5.95 |
| 2025-04-01 | -5.68 |
| 2025-03-31 | -6.09 |
| 2025-03-28 | -6.37 |
| 2025-03-27 | -6.56 |